Breakingviews | TPG/IMS

Considered view

05 Nov 2009 20:12

Returning to health?

By Lauren Silva Laughlin

Simply complete all fields and click Submit.

First name

Last name

Email address

Email again

Company

Sector

Telephone

Country

I agree to the terms and conditions of use appropriate to my region.

About Us

Breakingviews.com is the world's leading source of agenda-setting financial insight. breakingviews has 25 correspondents and columnists based in London, New York, Paris, Washington, San Francisco and Madrid. Our aim is to become the lingua franca for the global financial community. Our real-time subscription service currently reaches around 15,000 financial professionals such as investment bankers, senior corporate executives, hedge fund managers, lawyers and private equity professionals.

We reach a broader audience of nearly 4.5m investors and opinion-formers via columns in the following influential newspapers: The New York Times (USA), The Telegraph (UK), The International Herald Tribune, Le Monde (France), El Pais and Cinco Dias (Spain), Handelsblatt (Germany), La Stampa (Italy), NRC Handelsblad (Netherlands), The National (UAE), The Business Times (Singapore), Mint (India) and L’Agefi (Switzerland).

The private equity firm is leading a buyout of drugs market research company IMS. But old-style LBO financing is missing. The buyers are putting in a whopping 40% as equity. The rest is coming courtesy of Goldman – and mostly from funds it manages, not its own balance sheet.

Sign up for a free trial to read the rest of this subscriber-only content, or if you are already a member please sign in here.

Forgotten your password? Get a password reminder.